Visualitza per autor "Hayashi, Hidetoshi"
Ara mostrant els elements 1-3 d 3
-
A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer
Yamamoto, Nobuyuki; Morán, Teresa; Gregorc, Vanesa; Dowell, Jonathan; Cedres Perez, Susana; Planchard, David; Hayashi, Hidetoshi (Springer, 2020-10) -
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
yu, helena; Goto, Yasushi; Hayashi, Hidetoshi; FELIP, ENRIQUETA; Yang, James Chih-Hsin; Reck, Martin (American Society of Clinical Oncology, 2023-12-10) -
HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
Yu, Helena A; Hayashi, Hidetoshi; Goto, Yasushi; Reck, Martin; Yang, James Chih-Hsin; FELIP, ENRIQUETA (Future Medicine, 2023-06)